Figure 2.

Comparative effectiveness concerning combined and individual endpoints. The proportion of patients in the unadjusted, multivariable adjusted (MVA) and propensity score‐matched (PSM) analyses attaining the primary combined endpoint of any reduction in HbA1c, body weight and systolic blood pressure (A); the combined endpoint of reduction in HbA1c >0.5%, body weight >2 kg and systolic blood pressure >2 mm Hg (B); or the composite target of final HbA1c ≤7.0%, body weight loss ≥3% and systolic blood pressure <140 mm Hg (C); change from baseline to the end of follow‐up in HbA1c (D), body weight (E) and systolic blood pressure (F) in the unadjusted, MVA and PSM analyses. *P < 0.05 for the indicated comparison. The histograms in panels D through F indicate mean and SEM